The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: A report of the U.K. Managed Access Program.
Marco Maruzzo
No relevant relationships to disclose
Attila Kollar
No relevant relationships to disclose
Charlotte Benson
No relevant relationships to disclose
Christina Messiou
No relevant relationships to disclose
Elizabeth Cartwright
No relevant relationships to disclose
Beatrice M. Seddon
No relevant relationships to disclose
Palma Dileo
No relevant relationships to disclose
Aisha Miah
No relevant relationships to disclose
Juan Martin-Liberal
No relevant relationships to disclose
Khin Thway
No relevant relationships to disclose
Ellen McGrath
No relevant relationships to disclose
Alison Dunlop
No relevant relationships to disclose
Ian Robert Judson
No relevant relationships to disclose
Mark David Linch
Expert Testimony - Bayer (U)